ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

COG Cambridge Cognition Holdings Plc

56.20
1.20 (2.18%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.20 2.18% 56.20 54.00 55.00 54.50 54.50 54.50 21,504 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -46.58 18.99M
Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 55p. Over the last year, Cambridge Cognition shares have traded in a share price range of 48.80p to 105.50p.

Cambridge Cognition currently has 34,852,833 shares in issue. The market capitalisation of Cambridge Cognition is £18.99 million. Cambridge Cognition has a price to earnings ratio (PE ratio) of -46.58.

Cambridge Cognition Share Discussion Threads

Showing 76 to 98 of 875 messages
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
16/6/2014
14:26
Very illiquid with only 20% in public hands and with no buyers the spread is widening with every sell.
battlebus2
06/6/2014
15:26
Beggars belief at times this stock market. Some selling on the good contract news but as ever this is a long game and I intend to see these trading At £1 plus.
battlebus2
06/6/2014
14:12
Seems to be a seller around to spoil the fun here.
battlebus2
05/6/2014
17:00
Thanks for the Finn cap note Cheshire Man, hopefully the Sharesoc presentation will bring us to the attention of a few more investors.
It's a shame we didn't finish the day blue.

battlebus2
05/6/2014
16:57
ShareSoc Company Seminar Announcement



The line-up for our next seminar at which public companies will be presenting on the 25th June is now complete and is given below. This event is in the City of London, with registration starting at 4.00 pm. Four companies will be presenting this month and answering your questions, which are:



- Cambridge Cognition (COG): Cognitive assessment software for use in clinical trials, research and healthcare provision.

cheshire man
05/6/2014
09:23
Finncap retains £1 tp "with comfort" :-)


Major Cantab Solutions contract CORP
A £1.6m contract to provide cognitive safety assessment on a Phase III trial
of a cardiovascular drug has been signed. Whilst we are making no
changes to our forecasts, this major contract provides confidence in our
full-year estimates.
􀀗Contract details. The contract, totalling £1.6m, is to provide cognitive testing
support for a global multi-year Phase III study of a cardiovascular drug being
developed by an unnamed major biopharmaceutical company. The cognitive
testing is to evaluate the CNS safety of the drug.
􀀗Implications. Increasingly, there is a regulatory requirement to assess
cognitive side effects of drugs, even if they are not indicated for a CNS
condition, and this contract illustrates that Cambridge Cognition's battery of
cognitive function tests can be deployed in such a way in a highly regulated
environment. Cambridge Cognition anticipates that £0.8m of revenue will be
recognised in the current financial year. Whilst we make no changes to our
forecasts, this contract provides us with comfort in our £2.8m revenue forecast
for Cantab Solutions this year.

cheshire man
05/6/2014
06:55
Nice news for us this morning :-)
cheshire man
05/6/2014
06:33
Morning janeann, given turnover last year was 4 million this is a sizeable contract win. Worth a small punt under 70p imv.
battlebus2
05/6/2014
06:27
That does look positive battlebus. I hadn't considered that angle for COGs tests; I was less positive on the early dementia screening as I am not certain how the results might be used, but will look a little more closely at this company now.
janeann
30/5/2014
10:52
Shareholders and potential investors in Cambridge Cognition will probably be interested in attending ShareSoc's growth company seminar where COG will be presenting. More at: hxxp://www.sharesoc.org/seminarjune2014.html
sharesoc
28/5/2014
07:47
Beat me to it bb:-)
cheshire man
28/5/2014
06:12
More good news this morning....

Cantab Mobile rolled out in North East Lincolnshire CCG

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces that North East Lincolnshire Clinical Commissioning Group ('CCG') has recently introduced the Cantab Mobile app in five GP surgeries, five pharmacies and Grimsby hospital to help diagnose dementia earlier.

North East Lincolnshire is the latest CCG to roll out Cantab Mobile into GP surgeries, pharmacies and hospitals making the total number of CCGs rolled out in the UK 28. This technology has been introduced as part of a three-month evaluation. Cantab Mobile is the leading medical software for primary care allowing doctors to detect the earliest signs of clinically relevant memory problems by asking the patients to remember and match different shapes and patterns that appear on the iPad.

In April 2013 the Company announced the specifications from the NHS Commissioning Board for the four new directed enhanced services ('DES') that were to be offered to GP practices in 2013/14. For dementia this has now been extended into 2014/15. The specification prioritises, amongst other conditions, the timely diagnosis and support for people with dementia. This means that by rolling out Cantab Mobile the GP surgeries can expect to receive financial incentives to test anyone in the community, encouraging earlier diagnosis in the community.

Commenting, Nick Kerton, Chief Executive Officer of Cambridge Cognition, said: "Dementia currently costs the UK over £2.3 billion a year and if we are going to reduce this figure, early diagnosis is key. We are therefore extremely pleased that North East Lincolnshire has adopted Cantab Mobile to improve diagnosis rates in the area."

battlebus2
24/5/2014
11:32
Featured in Shares magazine this week. Positive article and states we should produce a maiden profit next year.
battlebus2
14/5/2014
08:05
Sharesoc growth company event has COG attending, the new date is 25th June.
battlebus2
08/5/2014
06:07
Fairly upbeat...AGM Statement

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

As I outlined in our Preliminary Results statement the business now has a clear strategic focus and we have in place a commercial infrastructure which will allow us to convert our wealth of scientific know-how into sustainable and growing commercial sales.

We have had a positive start to trading in the first quarter of the new financial year and remain confident that we will return the business to growth in 2014.

battlebus2
07/4/2014
09:13
Reminder that shareholders and potential investors in Cambridge Cognition will probably be interested in attending this event on the Sharesoc website: www.sharesoc.org/seminarmay2014.html
sharesoc
02/4/2014
06:10
Directorate Change

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Michael Lewis as Non-Executive Chairman. Michael joined the Board of Cambridge Cognition in 2013 as a Non-Executive Director and has gained over 25 years' experience in the global health and pharma industry.

Dr Jane Worlock, currently Non-Executive Chairman of the Company, has given notice to the Company of her intention to resign and will step down from the conclusion of the Company's forthcoming AGM, at which point Michael Lewis' appointment will take effect.

battlebus2
01/4/2014
22:01
Good to see them presenting and helping raise their profile to potential investors.
battlebus2
01/4/2014
21:34
Shareholders and potential investors in Cambridge Cognition will probably be interested in attending this event under the events tab at the Sharesoc website: www.sharesoc.org/seminarmay2014.html
sharesoc
16/3/2014
11:50
An interview with Andrew Blackwell from January 2013.

hxxp://www.news-medical.net/news/20130108/Dementia-diagnosis-an-interview-with-Dr-Andrew-Blackwell-Chief-Scientific-Officer-Cambridge-Cognition.aspx

battlebus2
14/3/2014
15:54
Ticking up again :))
battlebus2
14/3/2014
07:05
Nesta report features Cambridge Cognition

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, welcomes the publication of The Nesta report where the Company features heavily, in regards to the new wave of medtech companies leading the UK's Silicon Valley revolution.

Nesta is the UK's innovation foundation, an independent charity, helping people and organisations bring ideas to life. In this report, Silicon Valley Comes to the UK (SVC2UK) and Nesta present an overview of innovative companies and how they will play into changes in the broader healthcare sector.

Cambridge Cognition is listed as one of the companies that manages the complex relationships between doctors, researchers and government policy. The Company also features due to the technology being used in several hundred clinical research sites in over 50 countries, testing patients' cognitive function to enable faster diagnosis, as well as being used in clinical trials. Connectivity has enabled real-time data streaming and visualisation allowing the Company technology to check patient responses against expectations, measure, monitor and recommended procedural modifications (e.g. to accelerate patient enrolment) for research and clinical institutions even as the trial is progressing - reducing costs and improving data quality. Cambridge Cognition's research team use this information to test the underlying software, providing phased update of reference standards for assessing patients.

For the full report please visit:
hxxp://www.nesta.org.uk/sites/default/files/refilling_the_innovators_prescription.pdf

battlebus2
13/3/2014
21:10
continuing to watch
ukinvestor220
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock